View in EDS

Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin.

Saved in:
Bibliographic Details
Title: Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin.
Authors: Dao Thi, V.L., Debing, Y., Wu, X., Rice, C.M., Neyts, J., Moradpour, D., Gouttenoire, J.
Publication Year: 2016
Collection: Université de Lausanne (UNIL): Serval - Serveur académique lausannois
Subject Terms: Antiviral Agents/administration & dosage, Antiviral Agents/pharmacology, Chronic Disease, Drug Synergism, Drug Therapy, Combination, Hepatitis E/drug therapy, Hepatitis E virus/drug effects, Hepatitis E virus/physiology, Humans, In Vitro Techniques, RNA, Viral/drug effects, Viral/physiology, Ribavirin/administration & dosage, Ribavirin/pharmacology, Sofosbuvir/administration & dosage, Sofosbuvir/pharmacology, Virus Replication/drug effects
Description: Infection with hepatitis E virus genotype 3 may result in chronic hepatitis in immunocompromised patients. Reduction of immunosuppression or treatment with ribavirin or pegylated interferon-α can result in viral clearance. However, safer and more effective treatment options are needed. Here, we show that sofosbuvir inhibits the replication of hepatitis E virus genotype 3 both in subgenomic replicon systems as well as a full-length infectious clone. Moreover, the combination of sofosbuvir and ribavirin results in an additive antiviral effect. Sofosbuvir may be considered as an add-on therapy to ribavirin for the treatment of chronic hepatitis E in immunocompromised patients.
Document Type: article in journal/newspaper
Language: English
ISSN: 1528-0012
Relation: Gastroenterology; https://iris.unil.ch/handle/iris/140022; serval:BIB_9D8D1725E989; 000366832800025
DOI: 10.1053/j.gastro.2015.09.011
Availability: https://iris.unil.ch/handle/iris/140022
https://doi.org/10.1053/j.gastro.2015.09.011
Accession Number: edsbas.2A9E433E
Database: BASE
Description
Abstract:Infection with hepatitis E virus genotype 3 may result in chronic hepatitis in immunocompromised patients. Reduction of immunosuppression or treatment with ribavirin or pegylated interferon-α can result in viral clearance. However, safer and more effective treatment options are needed. Here, we show that sofosbuvir inhibits the replication of hepatitis E virus genotype 3 both in subgenomic replicon systems as well as a full-length infectious clone. Moreover, the combination of sofosbuvir and ribavirin results in an additive antiviral effect. Sofosbuvir may be considered as an add-on therapy to ribavirin for the treatment of chronic hepatitis E in immunocompromised patients.
ISSN:15280012
DOI:10.1053/j.gastro.2015.09.011